Industry strategies requirement for drug development
The goal of WG4 is to establish close industry-academia collaborations to develop a novel class of safe and efficacious sigma-1 receptor ligands for the treatment of neurodegenerative and neurodevelopmental, cardiometabolic diseases, pain disorder and cancer. Industry partners will establish close ties with academic partners, to introduce academia to the requirements that are necessary for a successful drug development program. Also, industry partners will provide various courses that will enable academic partners to acquire knowledge to meet industry needs.
Leader:Prof. Andrea Fekete
Co-leader:Dr. Michal Geva
Tasks and Activities
Task 4.1
Collaboration with academic laboratories to define a process for characterization and optimization of compounds for future clinical development
Task 4.2
Collaboration with academic laboratories to create a “Taskforce” dedicated to developing sigma-1 receptor-specific biomarkers
Task 4.3
Identification of sigma-1 receptor gene variants that have the potential to moderate the effects of sigma-1 receptor activation
Task 4.4
Establish collaborations for joint experimental projects to evaluate novel CNS-acting, sigma-1 receptor-targeting drugs developed by the Action members and/or the members from Industries
Task 4.5
Implementation of a training plan on Technology Transfer and IP issues
Task 4.6
Organisation of visits to Industry partners and innovation clusters
Deliverables
D4.1
Definition of a process for characterization and optimization of compounds (reports, articles)
D4.2
Identify variants in sigma-1 receptor gene that potentially could define prognostic/diagnostic biomarkers in pathological indications (reports, articles)
D4.3
Development of training plans and implementation on Technology Transfer, IP issues and industry needs from academics (reports)